Esketamine Nasal Spray: What You Need to Know About Dissociation, Blood Pressure, and Monitoring

When traditional antidepressants fail, esketamine nasal spray-marketed as Spravato-offers a lifeline. But it’s not like taking a daily pill. This treatment comes with intense side effects, strict rules, and a monitoring system unlike anything else in depression care. If you or someone you know is considering esketamine, understanding what happens during and after each dose isn’t optional-it’s essential.

How Esketamine Works (And Why It’s Different)

Most antidepressants target serotonin, norepinephrine, or dopamine. Esketamine doesn’t. Instead, it blocks NMDA receptors in the brain, which are part of the glutamate system. This is a completely different pathway. Think of it like rerouting traffic: while other drugs tweak mood chemicals slowly, esketamine triggers a rapid cascade of neural activity. That’s why some patients feel better within hours, not weeks.

It’s not magic. It’s science. And that science comes with side effects that can’t be ignored. The most common? Dissociation and spikes in blood pressure. These aren’t rare blips-they’re expected, predictable, and carefully managed.

Dissociation: Feeling Unreal, But Not Alone

If you’ve ever heard someone describe esketamine as making them feel “like they’re in a dream,” they’re not exaggerating. In clinical trials, over half of patients (56.2%) experienced dissociation during their first few treatments. That’s more than four times higher than placebo.

Symptoms vary. Some feel detached from their body. Others say time slows down or the room feels distant. A few report mild hallucinations-seeing shapes, hearing echoes, or feeling like they’re floating. These aren’t signs of psychosis. They’re direct effects of the drug on brain circuits.

The good news? It doesn’t last. Dissociation usually peaks around 40 minutes after the spray and fades within 1.5 to 2 hours. By the fourth or fifth treatment, many patients say it’s much milder. One user on Reddit wrote: “My first session felt like I was watching myself from the ceiling. By session four, I just felt a little floaty for 20 minutes.”

Clinics use a tool called the CADSS (Clinician-Administered Dissociative States Scale) to measure this. Scores above 3 mean severe dissociation-and that’s rare. Only 6.3% of patients hit that level. Still, every clinic is required to monitor it. No exceptions.

Blood Pressure Spikes: The Hidden Risk

While dissociation gets most of the attention, blood pressure changes are just as critical. Esketamine causes a rapid, temporary rise in both systolic and diastolic pressure. On average, systolic pressure jumps 14-23 mmHg. Diastolic goes up 7-16 mmHg. That’s enough to trigger warning signs in people with heart conditions.

In trials, 32.7% of patients had treatment-emergent hypertension-meaning their blood pressure climbed above 140/90. Compare that to 14.2% on placebo. It’s not just a number. For someone with untreated high blood pressure or a history of stroke, this could be dangerous.

That’s why you can’t just show up and get sprayed. Before treatment, your blood pressure is checked. Then, every 5-10 minutes for the first 30-40 minutes. After that, every 15-30 minutes. If your pressure climbs too high-say, above 180/110-the session is stopped. You’re sent home. No exceptions.

People with uncontrolled hypertension (BP over 160/100) are excluded from treatment. So are those with recent heart attacks, aneurysms, or brain malformations. These aren’t arbitrary rules. They’re based on real cases where unmonitored use led to serious outcomes.

The REMS Program: Why You Can’t Take It Home

Esketamine is one of the few medications in the U.S. that requires a Risk Evaluation and Mitigation Strategy (REMS). That means you can’t get it from a pharmacy. You can’t self-administer. You must go to a certified clinic, sit in a monitored room, and stay for at least two hours after the spray.

The process is rigid:

• You arrive and check in.
• Your blood pressure, heart rate, and oxygen levels are taken.
• You’re given the spray-self-administered under staff supervision.
• You sit quietly in a dim, calm room for two hours.
• Staff check your vitals every 5-10 minutes.
• At 40 minutes, they assess dissociation using the CADSS.
• You can’t leave until the two hours are up, even if you feel fine.

This isn’t bureaucracy. It’s safety. In 2022, only 5% of clinics ever let patients leave early-and even then, only if every single vital sign was stable and the patient was fully oriented.

Clinics spend an average of $18,500 to set up a Spravato room. They need private spaces, emergency oxygen, and staff trained in managing dissociation. Many also use electronic systems that auto-alert if blood pressure spikes. It’s expensive. But it’s necessary.

What Patients Really Say

Real-world feedback paints a mixed picture. On Healthgrades, Spravato has a 3.7/5 rating. 62% of reviewers mention dissociation. 41% say it’s manageable. 21% call it severe-but still temporary. One patient wrote: “I cried during my first session because I felt so disconnected. But by week three, I was calm. And for the first time in years, I felt hope.”

On the flip side, a user with pre-existing hypertension shared: “My systolic hit 170. They stopped the session. I had to quit. I’m not willing to risk a stroke for this.”

The common thread? People who stayed in the program overwhelmingly credit the staff. “They knew exactly what to do,” said 91% of positive reviewers on Drugs.com. That’s not luck. It’s training.

Access and the Future

As of 2023, over 2,800 clinics in the U.S. are certified to give Spravato. That’s up from 350 at launch. But access is still unequal. Urban areas have 3.2 clinics per 100,000 people. Rural areas? Just 0.8. Many patients drive hours to reach one.

In September 2023, the FDA approved a new option: for select patients, monitoring can be shortened from two hours to one. This applies only if the patient’s first few treatments show stable vitals and minimal dissociation. It’s a small step-but it’s progress.

Companies are working on alternatives. Oral versions. Less dissociative compounds. Digital tools that let patients monitor themselves at home. But none have matched esketamine’s speed or effectiveness in treatment-resistant depression.

Final Thoughts

Esketamine nasal spray isn’t for everyone. It’s not a first-line treatment. It’s not a quick fix. But for those who’ve tried everything else and still can’t get out of bed, it’s one of the few options left.

The dissociation? It’s intense, but brief. The blood pressure spike? It’s predictable, and monitored. The two-hour wait? It’s inconvenient-but it saves lives.

If you’re considering this, ask your doctor: Have you treated others with this? What’s your protocol for handling dissociation? Do you have emergency meds on hand? If they hesitate, keep looking. This isn’t a treatment you want to stumble into.

This isn’t just medicine. It’s a system. And the system works-because it’s designed to keep you safe while giving you a chance to feel like yourself again.